RGEN
Repligen Corporation NASDAQ Listed Apr 29, 1986$126.54
Mkt Cap $7.1B
52w Low $109.50
25.7% of range
52w High $175.77
50d MA $120.82
200d MA $138.12
P/E (TTM)
134.7x
EV/EBITDA
56.8x
P/B
3.1x
Debt/Equity
0.3x
ROE
2.3%
P/FCF
98.1x
RSI (14)
—
ATR (14)
—
Beta
1.19
50d MA
$120.82
200d MA
$138.12
Avg Volume
1.1M
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Building 1 · Waltham, MA 02453 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | BMO | 0.44 | 0.49 | +11.4% | 135.40 | -9.7% | -0.5% | -1.9% | +1.1% | -3.7% | -2.9% | — |
| Oct 28, 2025 | BMO | 0.42 | 0.46 | +9.5% | 161.10 | +2.4% | -5.9% | -2.0% | -2.6% | +3.1% | +0.7% | — |
| Jul 29, 2025 | BMO | 0.40 | 0.37 | -7.5% | 119.65 | +5.3% | +4.7% | -2.0% | -4.7% | +1.6% | -2.0% | — |
| Apr 29, 2025 | BMO | 0.35 | 0.39 | +11.4% | 143.63 | -5.9% | -2.9% | -1.0% | -0.6% | +3.1% | -0.4% | — |
| Feb 20, 2025 | BMO | 0.41 | 0.44 | +7.3% | 150.73 | +4.8% | +7.9% | -2.3% | +3.6% | -2.0% | +0.8% | — |
| Nov 12, 2024 | BMO | 0.34 | 0.43 | +28.2% | 139.51 | +5.7% | +6.5% | +1.3% | -5.3% | -12.4% | -1.1% | — |
| Jul 30, 2024 | BMO | 0.33 | 0.33 | +0.0% | 138.00 | +10.6% | +16.4% | +4.2% | -1.0% | -2.4% | +0.3% | — |
| May 1, 2024 | BMO | 0.29 | 0.28 | -3.4% | 164.20 | -3.2% | -3.6% | +5.0% | +0.4% | +0.6% | -0.2% | — |
| Feb 21, 2024 | BMO | 0.34 | 0.33 | -2.9% | 199.73 | -6.0% | -2.8% | -0.4% | +1.6% | -2.4% | +0.5% | — |
| Oct 31, 2023 | BMO | 0.14 | 0.23 | +64.3% | 114.17 | +17.9% | +17.9% | -2.3% | +3.9% | +10.1% | -4.3% | — |
| Aug 2, 2023 | BMO | 0.49 | 0.53 | +8.2% | 167.12 | -1.1% | +2.0% | -0.9% | +2.3% | -0.8% | +0.9% | — |
| May 2, 2023 | BMO | 0.59 | 0.64 | +8.5% | 153.54 | +2.0% | +2.4% | +3.9% | -3.8% | +1.9% | -2.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Canaccord Genuity | Maintains | Hold → Hold | — | $131.21 | $130.82 | -0.3% | +0.6% | +0.5% | -6.3% | -8.3% | +3.1% |
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $122.59 | $124.11 | +1.2% | +6.9% | +0.7% | -3.7% | +3.2% | +0.6% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $117.78 | $117.23 | -0.5% | -0.7% | -1.4% | +3.9% | +0.0% | +0.3% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $113.88 | $118.60 | +4.1% | +2.2% | -0.0% | -1.7% | +0.1% | -3.8% |
| Feb 25 | Wells Fargo | Maintains | Overweight → Overweight | — | $134.67 | $134.88 | +0.2% | -1.9% | +1.1% | -3.7% | -2.9% | -1.5% |
| Feb 25 | Barclays | Maintains | Overweight → Overweight | — | $134.67 | $134.88 | +0.2% | -1.9% | +1.1% | -3.7% | -2.9% | -1.5% |
| Feb 25 | UBS | Maintains | Buy → Buy | — | $134.67 | $134.88 | +0.2% | -1.9% | +1.1% | -3.7% | -2.9% | -1.5% |
| Feb 25 | Evercore ISI | Maintains | Outperform → Outperform | — | $134.67 | $134.88 | +0.2% | -1.9% | +1.1% | -3.7% | -2.9% | -1.5% |
| Jan 16 | UBS | Maintains | Buy → Buy | — | $161.69 | $162.29 | +0.4% | +0.2% | +0.8% | +4.1% | -1.2% | -3.3% |
| Dec 15 | Barclays | Maintains | Overweight → Overweight | — | $157.39 | $159.86 | +1.6% | +2.0% | -1.6% | -0.7% | +0.5% | +3.0% |
| Dec 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $157.39 | $159.86 | +1.6% | +2.0% | -1.6% | -0.7% | +0.5% | +3.0% |
| Oct 29 | Barclays | Maintains | Overweight → Overweight | — | $151.57 | $149.92 | -1.1% | -2.0% | -2.6% | +3.1% | +0.7% | -2.2% |
| Oct 29 | Canaccord Genuity | Maintains | Hold → Hold | — | $151.57 | $149.92 | -1.1% | -2.0% | -2.6% | +3.1% | +0.7% | -2.2% |
| Oct 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $150.10 | $150.31 | +0.1% | -2.8% | +3.3% | -1.3% | -2.4% | +2.4% |
| Oct 2 | Barclays | Maintains | Overweight → Overweight | — | $145.81 | $146.40 | +0.4% | -0.4% | +2.4% | +0.9% | -2.8% | +3.3% |
| Sep 22 | Evercore ISI | Upgrade | In Line → Outperform | — | $122.30 | $124.93 | +2.2% | +3.0% | -1.6% | +0.5% | -2.3% | +3.2% |
| Sep 12 | Jefferies | Maintains | Hold → Hold | — | $119.51 | $118.48 | -0.9% | -5.0% | +0.2% | +5.3% | -0.3% | +4.2% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $120.69 | $119.96 | -0.6% | -3.7% | +3.8% | +3.3% | -3.1% | -1.7% |
| Jul 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $125.30 | $126.33 | +0.8% | -2.0% | -4.7% | +1.6% | -2.0% | -0.5% |
| Jul 30 | RBC Capital | Maintains | Outperform → Outperform | — | $125.30 | $126.33 | +0.8% | -2.0% | -4.7% | +1.6% | -2.0% | -0.5% |
| Jul 8 | Evercore ISI | Maintains | In Line → In Line | — | $124.43 | $124.73 | +0.2% | +3.3% | +1.0% | +3.2% | -2.8% | -6.8% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $141.51 | $140.28 | -0.9% | -0.4% | -7.5% | -2.7% | +0.8% | -3.6% |
| Apr 30 | RBC Capital | Maintains | Outperform → Outperform | — | $139.43 | $139.54 | +0.1% | -1.0% | -0.6% | +3.1% | -0.4% | -7.5% |
| Apr 29 | JP Morgan | Maintains | Overweight → Overweight | — | $143.63 | $135.15 | -5.9% | -2.9% | -1.0% | -0.6% | +3.1% | -0.4% |
| Apr 16 | Canaccord Genuity | Maintains | Hold → Hold | — | $126.62 | $127.90 | +1.0% | +4.3% | -1.6% | +1.3% | +5.5% | +1.8% |
| Feb 21 | RBC Capital | Maintains | Outperform → Outperform | — | $162.67 | $164.34 | +1.0% | -2.3% | +3.6% | -2.0% | +0.8% | -3.9% |
| Feb 21 | JP Morgan | Maintains | Overweight → Overweight | — | $162.67 | $164.34 | +1.0% | -2.3% | +3.6% | -2.0% | +0.8% | -3.9% |
| Feb 21 | Canaccord Genuity | Maintains | Hold → Hold | — | $162.67 | $164.34 | +1.0% | -2.3% | +3.6% | -2.0% | +0.8% | -3.9% |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $162.67 | $164.34 | +1.0% | -2.3% | +3.6% | -2.0% | +0.8% | -3.9% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $166.84 | $164.87 | -1.2% | +0.6% | -1.2% | +1.3% | +3.7% | -2.8% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $167.92 | $168.53 | +0.4% | -0.6% | +0.6% | -1.2% | +1.3% | +3.7% |
| Sep 26 | RBC Capital | Maintains | Outperform → Outperform | — | $139.60 | $143.21 | +2.6% | +5.4% | -0.8% | +2.0% | -2.1% | -1.7% |
| Jul 31 | RBC Capital | Maintains | Outperform → Outperform | — | $160.59 | $160.97 | +0.2% | +4.2% | -1.0% | -2.4% | +0.3% | +1.0% |
| Jul 31 | JP Morgan | Maintains | Overweight → Overweight | — | $160.59 | $160.97 | +0.2% | +4.2% | -1.0% | -2.4% | +0.3% | +1.0% |
| Jul 31 | UBS | Maintains | Buy → Buy | — | $160.59 | $160.97 | +0.2% | +4.2% | -1.0% | -2.4% | +0.3% | +1.0% |
| Jul 30 | Stephens & Co. | Maintains | Overweight → Overweight | — | $138.00 | $152.68 | +10.6% | +16.4% | +4.2% | -1.0% | -2.4% | +0.3% |
| Jun 26 | Deutsche Bank | Upgrade | Hold → Buy | — | $123.15 | $126.74 | +2.9% | +3.1% | -0.3% | -0.4% | -2.2% | -2.6% |
| May 2 | JP Morgan | Maintains | Overweight → Overweight | — | $158.36 | $160.61 | +1.4% | +5.0% | +0.4% | +0.6% | -0.2% | -1.3% |
| Feb 22 | Stifel | Maintains | Buy → Buy | — | $194.10 | $197.28 | +1.6% | -0.4% | +1.6% | -2.4% | +0.5% | +1.7% |
| Feb 15 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $206.04 | $207.60 | +0.8% | -0.0% | +1.2% | -4.2% | -2.8% | -0.4% |
| Dec 20 | JP Morgan | Maintains | Overweight → Overweight | — | $182.10 | $182.99 | +0.5% | -1.3% | +1.3% | +0.3% | +0.5% | +0.0% |
| Dec 4 | Benchmark | Downgrade | Buy → Hold | — | $164.94 | $161.60 | -2.0% | -2.1% | -4.3% | +1.1% | +3.6% | -1.6% |
| Nov 2 | UBS | Maintains | Buy → Buy | — | $131.46 | $137.50 | +4.6% | +3.9% | +10.1% | -4.3% | +4.9% | -2.0% |
| Nov 1 | Stifel | Maintains | Buy → Buy | — | $134.56 | $132.92 | -1.2% | -2.3% | +3.9% | +10.1% | -4.3% | +4.9% |
| Nov 1 | RBC Capital | Maintains | Outperform → Outperform | — | $134.56 | $132.92 | -1.2% | -2.3% | +3.9% | +10.1% | -4.3% | +4.9% |
| Nov 1 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $134.56 | $132.92 | -1.2% | -2.3% | +3.9% | +10.1% | -4.3% | +4.9% |
| Oct 17 | JP Morgan | Maintains | Overweight → Overweight | — | $153.16 | $149.24 | -2.6% | -4.8% | -2.3% | +2.6% | -0.2% | -1.5% |
| Sep 8 | RBC Capital | Maintains | Outperform → Outperform | — | $168.20 | $168.62 | +0.2% | -4.0% | +1.0% | -3.2% | +0.7% | +4.0% |
| Sep 6 | RBC Capital | Maintains | Outperform → Outperform | — | $169.41 | $168.62 | -0.5% | -1.0% | +0.3% | -4.0% | +1.0% | -3.2% |
| Aug 3 | Stephens & Co. | Maintains | Overweight → Overweight | — | $170.48 | $168.35 | -1.2% | -0.9% | +2.3% | -0.8% | +0.9% | -0.0% |
No insider trades available.
8-K · 2.02
!! High
Repligen Corporation -- 8-K 2.02: Earnings Results
Repligen Corporation reported Q1 2026 financial results, providing investors with updated performance metrics and guidance for evaluating the bioprocess technology company's operational trajectory.
May 5
8-K
Repligen Corp -- 8-K Filing
Repligen achieved 14% organic growth in Q4 2025 driven by Analytics and Proteins segments, positioning the company favorably heading into 2026 with updated full-year guidance.
Feb 24
Data updated apr 26, 2026 10:39pm
· Source: massive.com